Full-Time

Associate Director

Pharmacometrician

Posted on 8/22/2025

Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$135.1k - $225.1k/yr

+ Bonus

No H1B Sponsorship

Cambridge, MA, USA + 3 more

More locations: Canterbury, UK | Groton, CT, USA | New York, NY, USA

Hybrid

Relocation assistance may be available based on business needs and/or eligibility.

Category
Medical, Clinical & Veterinary (1)
Required Skills
R
Requirements
  • PhD or equivalent degree with strong quantitative skills (e.g., pharmacometrics, pharmacokinetics, mechanistic modeling/systems pharmacology, statistics)
  • 3 years or more of experience in a quantitative field
  • Expertise in analysis and programming software (e.g., Nonmem, R)
  • Experience in pharmacometric analyses
  • Good communication skills (written, oral)
  • Drug development and/or regulatory experience
  • Publications in relevant discipline
  • Good understanding of Pharmacokinetics, Pharmacodynamics and Statistical Principles
  • Candidate demonstrates a breadth of diverse leadership experiences and capabilities including: the ability to influence and collaborate with peers, develop and coach others, oversee and guide the work of other colleagues to achieve meaningful outcomes and create business impact.
Responsibilities
  • Provide support in the development of quantitative methodology, pharmacometrics tools, software, hardware, and/or related business processes.
  • With guidance, provide MIDD expertise on multidisciplinary development teams, working closely with clinical pharmacologists, clinicians, and statisticians to create MIDD plans that include assessments of a drug’s efficacy, safety, and commercial viability.
  • Responsible for the planning and execution of relevant quantitative analyses which may include population pharmacokinetics, pharmacokinetics/pharmacodynamics, exposure response, disease progression modeling, model-based meta analysis, and decision analysis for multiple analyses supporting a program.
  • Prepare formal presentations and written reports to Pfizer standards.
  • Contribute to regulatory documents (summary documents, briefing books, regulatory responses)
  • Have a good understanding of literature, government guidelines, and internal guidance as relates to pharmacometrics and MIDD
  • Contribute to the development or improvement of our tools, processes and methodology, including involvement in internal cross-functional workgroups or initiatives, external alliances or committees, consortia and academic relationships.
Desired Qualifications
  • Experience using Nonmem, R and/or PsN softwares is preferred.
  • Candidates from alternative backgrounds (e.g. mathematics, engineering, system biology, medicine) will be considered if they can demonstrate relevant experience and expertise.

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Simplify Jobs

Simplify's Take

What believers are saying

  • Vyndamax exclusivity through mid-2031 provides a crucial revenue bridge.
  • Pfizer's 25-valent pneumococcal vaccine could expand beyond PREVNAR 20.
  • VEPPANU royalties and HYMPAVZI expansion diversify growth beyond legacy blockbusters.

What critics are saying

  • Eliquis, Ibrance, Xtandi, and Xeljanz patent cliffs hit 2026-2030.
  • COVID product revenue collapsed from $56.7 billion in 2022 to $5 billion in 2026.
  • Seagen integration and GLP-1 launch timing remain critical execution tests against stronger incumbents.

What makes Pfizer unique

  • Pfizer spans vaccines, oncology, rare diseases, and internal medicine globally.
  • May 5, 2026 pipeline update showed 96 total programs and 10 advances.
  • HYMPAVZI, PADCEV, and TALZENNA anchor multiple late-stage, commercially relevant programs.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Pfizer who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Company News

Pfizer
May 4th, 2026
Esperion Therapeutics Completes $22.75 M Series A Financing | Pfizer

ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--ANN ARBOR, Mich

Yahoo Finance
Apr 9th, 2026
Pfizer beats Q4 revenue estimates by 5.5% as branded pharma sector faces mixed earnings

Ten branded pharmaceuticals stocks reported mixed fourth-quarter results, with revenues missing analysts' consensus estimates by 1.7% on average. Share prices have declined 3% on average since the latest earnings results. Pfizer reported revenues of $17.56 billion, down 1.2% year-on-year but exceeding analysts' expectations by 5.5%. The stock has risen 2.8% since reporting and currently trades at $27.40. Eli Lilly delivered the strongest performance amongst peers, reporting revenues of $19.29 billion, up 42.6% year-on-year and beating expectations by 7.4%. Despite the impressive results, shares have fallen 5.2% since reporting to $951.77. The industry faces tailwinds from precision medicine advances and AI adoption, but headwinds include regulatory scrutiny, pricing pressures and patent cliffs for blockbuster drugs.

Yahoo Finance
Apr 7th, 2026
Pfizer stock seen as undervalued buy despite pipeline growth and strategic acquisitions

Pfizer, trading at less than 10 times estimated future earnings, presents significant upside potential despite recent revenue declines. The pharmaceutical company's sales fell from $101 billion in 2022 to under $63 billion last year as COVID-19 product revenues diminished. However, Pfizer has been actively preparing for growth through strategic acquisitions. In 2023, it purchased oncology specialist Seagen for $43 billion, gaining access to promising antibody-drug conjugates for cancer treatment. Last year, it acquired GLP-1 drugmaker Metsera for up to $10 billion to enter the anti-obesity drug market. The company maintains over 100 drug candidates in development. Whilst facing near-term patent cliffs on key drugs, Pfizer's extensive pipeline and low valuation suggest substantial long-term potential for investors willing to accept calculated risk.

Yahoo Finance
Apr 6th, 2026
Pfizer shares climb 7.1% in six months as organic revenue grows 10.1% annually

Pfizer shares have climbed to $28.30, delivering a 7.1% return over the past six months and outperforming the S&P 500 by 9.4 percentage points. The pharmaceutical company's organic revenue has grown at a solid 10.1% year-on-year average over the last two years, whilst its adjusted operating margin rose 17.8 percentage points to reach 35.1% for the trailing 12 months. However, Pfizer's long-term performance shows slower growth, with revenue expanding at just a 5.6% compound annual growth rate over the past five years, underperforming the broader healthcare sector. The stock currently trades at 9.6× forward price-to-earnings ratio. Founded in 1849, Pfizer develops and manufactures medicines and vaccines for various diseases and conditions globally.

Yahoo Finance
Mar 30th, 2026
Pfizer shares up 25% since Jim Cramer said 'pass' on Mad Money

Pfizer shares have risen 25% since Jim Cramer advised investors to "pass" on the stock in April 2025, citing uncertainty over potential tariffs and taxes on pharmaceutical companies. The shares are up 6.7% over the past year and 7.4% year-to-date. A notable gain occurred between 29 September and 1 October, when shares jumped 14% following Pfizer's announcement that it would lower Medicaid drug prices to match those in developing countries as part of the Trump administration's TrumpRx initiative. However, shares fell 3.3% on 3 February after the company reported fourth-quarter results of $17.6 billion in revenue and $0.66 adjusted earnings per share. Pfizer is developing a once-monthly weight loss treatment and currently offers an 8% dividend yield.

INACTIVE